Helen Gogas
National and Kapodistrian University of Athens
H-index: 73
Europe-Greece
Top articles of Helen Gogas
Title | Journal | Author(s) | Publication Date |
|---|---|---|---|
Reaching the Diagnosis of Checkpoint Inhibitor-Induced Diabetes Mellitus in Different Clinical Scenarios: A Real-World Application of Updated Diagnostic Criteria | Diseases | Anna Angelousi Dimitrios C Ziogas Vasiliki Siampanopoulou Chrysoula Mytareli Amalia Anastasopoulou | 2024/2/14 |
COLUMBUS 7-year update: a randomized, open-label, phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF V600E/K-mutant melanoma | European Journal of Cancer | Dirk Schadendorf Reinhard Dummer Keith T Flaherty Caroline Robert Ana Arance | 2024/4/24 |
Ten-year clinical outcome, toxicity and compliance of dose-dense sequential adjuvant administration of cyclophosphamide & epirubicin followed by docetaxel in patients with … | The Breast | Foteinos-Ioannis Dimitrakopoulos Anna Goussia Georgia-Angeliki Koliou Katerina Dadouli Anna Batistatou | 2024/2/1 |
Real-world management practices and characteristics of patients with advanced melanoma initiated on immuno-oncology or targeted therapy in the first-line setting during the … | Melanoma Research | Dimitrios Bafaloukos Panagiotis Kouzis Panagiotis Gouveris Ioannis Boukovinas Konstantinos Kalbakis | 2024/4/1 |
New Emerging Targets in Cancer Immunotherapy: The Role of B7-H3 | Ioannis-Alexios Koumprentziotis Charalampos Theocharopoulos Dimitra Foteinou Erasmia Angeli Amalia Anastasopoulou | 2024/1/5 | |
Analysis of biomarker and outcomes data: 7-year update from COLUMBUS | Cancer Research | Reinhard Dummer Keith Flaherty Shibing Deng Tao Xie Phineas Hamilton | 2024/3/22 |
Sequential immunotherapy and targeted therapy for metastatic BRAF V600 mutated melanoma: 4-year survival and biomarkers evaluation from the phase II SECOMBIT trial | Nature Communications | Paolo A Ascierto Milena Casula Jenny Bulgarelli Marina Pisano Claudia Piccinini | 2024/1/2 |
Associations of dietary factors with cutaneous melanoma: a case-control study in Greece with literature review | Andreas Katsimpris Antonios G Antoniadis Nick Dessypris Konstantinos Karampinos Helen J Gogas | 2024/3/12 | |
The side effect registry immuno-oncology (SERIO)–A tool for systematic analysis of immunotherapy-induced side effects | European Journal of Cancer | Carolin Ertl Theresa Ruf Dirk Mentzer Mingzi Kong Rafaela Kramer | 2024/3/1 |
Digging into the NGS Information from a Large-Scale South European Population with Metastatic/Unresectable Pancreatic Ductal Adenocarcinoma: A Real-World Genomic Depiction | Cancers | Dimitrios C Ziogas Eirini Papadopoulou Helen Gogas Stratigoula Sakellariou Evangellos Felekouras | 2023/12/19 |
1104P Efficacy of immune checkpoint inhibition in metastatic or non-resectable melanoma after failure of adjuvant anti-PD1 treatment: A EUMelareg real-world evidence study | Annals of Oncology | M Weichenthal D Schadendorf L Bastholt I Gavrilova JBAG Haanen | 2023/10/1 |
Overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAFV600 mutation-positive advanced melanoma (IMspire150): second interim … | The Lancet Oncology | Paolo A Ascierto Daniil Stroyakovskiy Helen Gogas Caroline Robert Karl Lewis | 2023/1/1 |
Bempegaldesleukin plus nivolumab in untreated advanced melanoma: the open-label, phase III PIVOT IO 001 trial results | Journal of Clinical Oncology | Adi Diab Helen Gogas Shahneen Sandhu Georgina V Long Paolo A Ascierto | 2023/10/20 |
COLUMBUS 5-year update: a randomized, open-label, phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF. | Reinhard Dummer Keith T Flaherty Caroline Robert Ana Arance C Garbe | 2023/6/13 | |
The uncharted landscape of rare endocrine immune-related adverse events | Chrysoula Mytareli Dimitrios C Ziogas Athina Karampela Petros Papalexis Vasiliki Siampanopoulou | 2023/3/28 | |
Endocrinopathies in oncological patients treated with immunotherapy: A real world data study | Endocrine Abstracts | Anna Angelousi Athina Karampela Spyridon Kazanas Petros Papalexis Alexandros Lafioniatis | 2023/5/2 |
LBA51 Unraveling relatlimab (RELA)-specific biology using biomarker analyses in patients with advanced melanoma treated with nivolumab (NIVO)+ RELA or NIVO alone in RELATIVITY-047 | Annals of Oncology | EJ Lipson S Dolfi H Tang H Gogas HA Tawbi | 2023/10/1 |
Diabetes insipidus: A rare endocrine complication of immune check point inhibitors: A case report and literature review | Experimental and Therapeutic Medicine | Anna Angelousi Petros Papalexis Athina Karampela Marianna Marra Dimitrios Misthos | 2023/1/1 |
Contribution of MEK Inhibition to BRAF/MEK inhibitor combination treatment of BRAF-Mutant melanoma: part 2 of the Randomized, Open-Label, phase III COLUMBUS Trial | Journal of Clinical Oncology | Paolo A Ascierto Reinhard Dummer Helen J Gogas Ana Arance Mario Mandala | 2023/10/10 |
COLUMBUS–Essai de phase III randomisé évaluant encorafénib (enco)+ binimétinib (bini) vs vémurafénib (vému) ou enco chez des patients atteints d’un mélanome avec mutation BRAF … | Annales de Dermatologie et de Vénéréologie-FMC | C Robert D Schadendorf R Dummer KT Flaherty A Arance | 2023/12/1 |
